Menu
Back to Journals » Neuropsychiatric Disease and Treatment » Volume 9
New approaches for the management of bipolar disorder: role of sublingual asenapine in the treatment of mania
Authors Warren CG, Dubovsky SL
Received 11 March 2013
Accepted for publication 18 April 2013
Published 24 May 2013 Volume 2013:9 Pages 753—758
DOI https://doi.org/10.2147/NDT.S16078
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 5
Calvert G Warren,1 Steven L Dubovsky1,2
1Department of Psychiatry, State University of New York at Buffalo, Buffalo, NY, USA; 2Departments of Psychiatry and Medicine, University of Colorado, Boulder, CO, USA
Abstract: Bipolar disorder is a prevalent disorder that tends to become progressive without treatment and with inadequate treatment. Second generation (atypical) antipsychotic drugs have increasingly been used as adjunctive treatment or monotherapy for mania, but they have the potential for significant adverse effects and their role in maintenance treatment remains unclear. Asenapine is a new atypical antipsychotic medication formulated in a sublingual preparation that has been studied for mania but not maintenance therapy. Evidence indicating efficacy, adverse effects, and potential benefits and drawbacks of using asenapine in the treatment of bipolar disorder based on currently available published data are summarized.
Keywords: bipolar disorder, antipsychotic drug, mania, maintenance, sublingual
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.